Literature DB >> 25126201

Diagnostic and prognostic roles of DOG1 and Ki-67, in GIST patients with localized or advanced/metastatic disease.

Didem Sözütek1, Serdar Yanık2, Ayşe Neslin Akkoca3, Alper Sözütek4, Zeynep Tuba Ozdemir5, Ciğdem Usul Avşar6, Meral Günaldı7, Berksoy Sahin8, Figen Doron9.   

Abstract

AIM: Gastrointestinal stromal tumor is the most common mesenchymal neoplasia in the gastrointestinal tract and has a broad spectrum of pathological patterns and also clinical features changing from benign to malignant. Although the well-characterized parameters to predict the outcome have been the size and the mitotic index of the tumor in the patients with early-staged disease, bulky recurrent or metastatic tumor, resistance to medical treatment and mutation analysis are the prognostic factors for advanced stage-GIST. The aim of this study is to investigate new and more practical tissue markers, such as DOG1 and Ki-67 to specify the GIST diagnosis and also to predict the outcome in GIST patients with both localized and advanced staged disease.
METHODS: For the last 14 years, from 1999 to 2013, 111 patients with a histopathological GIST diagnosis from the hospital files were enrolled to the study. In their parafin-embedded tissue samples, DOG1 and Ki-67 expressions were evaluated with immunohistochemisty by two independent pathologists from Cukurova University Medical Faculty. Patients were divided into two groups, the patients with localized disease treated by surgery and the patients with advanced/metastatic disease. DOG1 and Ki-67 expressions were corelated with other diagnostic and prognostic histopathological markers and also the clinical outcome in these two group of patients.
RESULTS: The specificity and the sensitivity of DOG1 in GIST diagnosis was found 94 and 43%, respectively. DOG1 expression was especially important in the diagnosis of c-kit negative cases. Although Ki-67 was not found a statistically significant prognostic factor for overall survival, it was strongly corelated with mitotic index which is a well-known standart prognostic factor for localized disease. DISCUSSION: DOG1 seems to be an important diagnostic tool for clinically suspected GIST diagnosis in both advanced or early staged patients whose tumours are c-kit expression negative. On the other hand, Ki-67 can be a stronger candidate for prognostic factor instead of mitotic index to identify the proliferative cells out of mitotic phase but this statement needs be prospectively validated on studies with large number of patients.

Entities:  

Keywords:  DOG1; Gastrointestinal stromal tumor; Ki-67; prognostic factor

Year:  2014        PMID: 25126201      PMCID: PMC4132165     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  37 in total

1.  Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST).

Authors:  Ricardo Artigiani Neto; Angela Flavia Logullo; João Norberto Stávale; Laércio Gomes Lourenço
Journal:  Acta Cir Bras       Date:  2012-05       Impact factor: 1.388

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

4.  Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

Authors:  Markku Miettinen; Hala Makhlouf; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2006-04       Impact factor: 6.394

5.  Telomerase activity in gastrointestinal stromal tumors.

Authors:  S Sakurai; M Fukayama; Y Kaizaki; K Saito; K Kanazawa; M Kitamura; Y Iwasaki; T Hishima; Y Hayashi; M Koike
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

6.  Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: a series of 5 cases with molecular analysis.

Authors:  Wei-Lien Wang; Jason L Hornick; Raj Mallipeddi; Bettina G Zelger; Joshua D Rother; Dan Yang; Dina C Lev; Jonathan C Trent; Victor G Prieto; Thomas Brenn; Alistair Robson; Eduardo Calonje; Alexander J F Lazar
Journal:  Am J Dermatopathol       Date:  2009-05       Impact factor: 1.533

7.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

8.  Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.

Authors:  Tadashi Hasegawa; Yoshihiro Matsuno; Tadakazu Shimoda; Setsuo Hirohashi
Journal:  Hum Pathol       Date:  2002-06       Impact factor: 3.466

Review 9.  Best practices in diagnostic immunohistochemistry: spindle cell neoplasms of the gastrointestinal tract.

Authors:  Matthew S Turner; Jeffrey D Goldsmith
Journal:  Arch Pathol Lab Med       Date:  2009-09       Impact factor: 5.534

Review 10.  Malignant gastrointestinal stromal tumor of the gallbladder.

Authors:  Jong Kyung Park; Seung Hye Choi; Seong Lee; Ki Ouk Min; Sang Seob Yun; Hae Myung Jeon
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

View more
  7 in total

1.  Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers.

Authors:  Safinur Atay; Daniel W Wilkey; Mohammed Milhem; Michael Merchant; Andrew K Godwin
Journal:  Mol Cell Proteomics       Date:  2017-12-14       Impact factor: 5.911

2.  Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.

Authors:  Francesca Maria Rizzo; Raffaele Palmirotta; Andrea Marzullo; Nicoletta Resta; Mauro Cives; Marco Tucci; Franco Silvestris
Journal:  BMC Cancer       Date:  2016-02-11       Impact factor: 4.430

Review 3.  Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis.

Authors:  Yu Zhou; Wenqing Hu; Ping Chen; Masanobu Abe; Lei Shi; Si-Yuan Tan; Yong Li; Liang Zong
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.

Authors:  Yasemin Baskin; Gizem Calibasi Kocal; Betul Bolat Kucukzeybek; Mahdi Akbarpour; Nurcin Kayacik; Ozgul Sagol; Hulya Ellidokuz; Ilhan Oztop
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

5.  CT Radiomics for the Preoperative Prediction of Ki67 Index in Gastrointestinal Stromal Tumors: A Multi-Center Study.

Authors:  Yilei Zhao; Meibao Feng; Minhong Wang; Liang Zhang; Meirong Li; Chencui Huang
Journal:  Front Oncol       Date:  2021-09-14       Impact factor: 6.244

6.  Gastrointestinal Stromal Tumor and Ki-67 as a Prognostic Indicator.

Authors:  Kevin J Kadado; Oaklee L Abernathy; William J Salyers; K James Kallail
Journal:  Cureus       Date:  2022-01-01

7.  Does Immunohistochemistry for Discovered on GIST1 and Minichromosome Maintenance Protein7 Provide Additional Clinicopathological Value in Gastrointestinal Stromal Tumors?

Authors:  Dalia Mohamed Abd El-Rehim; Mariana Fathy Gayyed
Journal:  World J Oncol       Date:  2015-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.